Six months of isoflavone supplement increases fat-free mass in obese-sarcopenic postmenopausal women: A randomized double-blind controlled trial

European Journal of Clinical Nutrition

Volumn 61, Issue 12, 2007, Pages 1442-1444

  Aubertin Leheudre, M ^b   Lord, C ^d   Khalil, A ^c   Dionne, I J ^a,b  

^a UNIVERSITY INSTITUTE OF GERIATRICS OF SHERBROOKE   (Canada)

^b Faculty of Physical Education and Sports   (Canada)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

DAIDZEIN; GENISTEIN; GLYCITEIN; ISOFLAVONE; PLACEBO;

ADULT; AGED; ARTICLE; BODY COMPOSITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; LEAN BODY WEIGHT; MUSCLE ATROPHY; MUSCLE MASS; OBESITY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL;

ABSORPTIOMETRY, PHOTON; AGED; AGING; BODY COMPOSITION; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOFLAVONES; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR ATROPHY; OBESITY; PHYTOESTROGENS; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 37049020466     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/sj.ejcn.1602695     Document Type: Article

References (21)

1. Aubertin-Leheudre M, Audet M, Goulet ED, Dionne IJ (2005). HRT provides no additional beneficial effect on sarcopenia in physically active postmenopausal women: A cross-sectional, observational study. Maturitas 51, 140-145.
2. Baumgartner RN, Wayne SJ, Waters DL, Janssen I, Gallagher D, Morley JE (2004). Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res 12, 1995-2004.
3. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR et al. (1998). Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147, 755-763.
4. Beauftere B, Morio B (2000). Fat and protein redistribution with aging: metabolic considerations. Eur J Clin Nutr 54 (Suppl 3), S48-S53.
5. Crisafulli A, Altavilla. D, Marini H, Bitto A, Cucinotta D, Frisina N et al. (2005). Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. Menopause 12, 186-192.
6. Dragan I, Stroescu V, Stoian I, Georgescu E, Baloescu. R (1992). Studies regarding the efficiency of Supro isolated soy protein in Olympic athletes. Rev Roum Physiol 29, 63-70.
7. Fox AA, Thompson JL, Butterfield GE, Gylfadottir U, Moynihan S, Spiller G (1996). Effects of diet and exercise on common cardiovascular disease risk factors in moderately obese older women. Am J Clin Nutr 63 225-233.
8. Greeves JP, Cable NT, Reilly T, Kingsland C (1999). Changes in muscle strength in women following the menopause: A longitudinal assessment of the efficacy of hormone replacement therapy. Clin Sci (Lond) 97 79-84.
9. Haarbo J, Marslew U, Gotfredsen A, Christiansen C (1991). Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism 40, 1323-1326.
10. Hermansen K, Sondergaard M, Hoie L, Carstensen M, Brock B (2001). Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects. Diabetes Care 24, 228-233.
11. Hsu CS, Shen WW, Hsueh YM, Yeh SL (2001). Soy isoflavone supplementation in postmenopausal women. Effects on plasma lipids, antioxidant enzyme activities and bone density. J Reprod Med 46, 221-226.
12. Janssen I, Heymsfield SB, Ross R (2002). Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 50, 889-896.
13. Lemoine S, Granier P, Tiffoche C, Rannou-Bekono F, Thieulant ML, Delamarche P (2003). Estrogen receptor alpha mRNA in human skeletal muscles. Med Sci Sports Exerc 35, 439-443.
14. Moeller LE, Peterson CT, Hanson KB, Dent SB, Lewis DS, King DS et al. (2003). Isoflavone-rich soy protein prevents loss of hip lean mass brut does not prevent the shift in regional fat distribution in perimenopausal women. Menopause 10, 322-331.
15. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 321-333.
16. Skelton DA, Phillips SK, Bruce SA, Naylor CH, Woledge RC (1999). Hormone replacement therapy increases isometric muscle strength of adductor pollicis in post-menopausal women. Clin Sci (Lond) 96, 357-364.
17. Sowers MR, Crutchfield M, Richards K, Wilkin MK, Furniss A, Jannausch M et al. (2005). Sarcopenia is related to physical functioning and leg strength in middle-aged women. J Gerontol A Biol Sci Med Sci 60, 486-490.
18. Tanko LB, Movsesyan L, Mouritzen U, Christiansen C, Svendsen OL (2002). Appendicular lean tissue mass and the prevalence of sarcopenia among healthy women. Metabolism 51, 69-74.
19. van der Schouw YT, Kreijkamp-Kaspers S, Peeters PH, Keinan-Boker L, Rimm. EB, Grobbee DE (2005). Prospective study on usual dietary phytoestrogen intake and cardiovascular disease risk in Western women. Circulation 111, 465-471.
20. Walker HA, Dean TS, Sanders TA, Jackson G, Ritter JM, Chowienczyk PJ (2001). The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17beta-estradiol. Circulation 103, 258-262.
21. Wu J, Wang X, Chiba H, Higuchi M, Nakatani T, Ezaki O et al. (2004). Combined intervention of soy isoflavone and moderate exercise prevents body fat elevation and bone loss in ovariectomized mice. Metabolism 53, 942-948.